For research use only. Not for therapeutic Use.
Tranexamic acid-d2-1 is the deuterium labeled Tranexamic acid[1]. Tranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM[2][3].
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
| Catalog Number | I041675 |
| CAS Number | 2714435-89-7 |
| Synonyms | 4-[amino(dideuterio)methyl]cyclohexane-1-carboxylic acid |
| Molecular Formula | C8H13D2NO2 |
| Purity | ≥95% |
| InChI | InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/i5D2 |
| InChIKey | GYDJEQRTZSCIOI-BFWBPSQCSA-N |
| SMILES | C1CC(CCC1CN)C(=O)O |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Bhat A, et al. Tranexamic acid overdosage-induced generalized seizure in renal failure. Saudi J Kidney Dis Transpl. 2014 Jan-Feb;25(1):130-2. [3]. Couturier R, et al. Continuous or discontinuous tranexamic acid effectively inhibits fibrinolysis in children undergoing cardiac surgery with cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2014 Jan 13. |
